Zeng H, Song J, Li Y, Guo C, Zhang Y, Yin T, et al
The answer is yesbut with important caveats about what that research shows and doesn't show
The conflicting safety signal One real-world evidence study found that patients receiving GLP-1 receptor agonists had higher risks of certain autoimmune conditions, including ulcerative colitis, rheumatoid arthritis, autoimmune thyroiditis, ankylosing spondylitis, and psoriasis, compared to those on DPP-4 inhibitors
Brand-name medications cost $969-$1,349/month without insurance
We've built the TrimrX program around this very principle
YL: Conceptualization, Visualization, Writing review and editing